Analyst Ratings For EXACT Sciences Corporation (NASDAQ:EXAS)
Today, Goldman Sachs Group raised its price target on EXACT Sciences Corporation (NASDAQ:EXAS) to $75.00 per share.
There are 9 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on EXACT Sciences Corporation (NASDAQ:EXAS) is Buy with a consensus target price of $76.50 per share, a potential 2.93% upside.
Some recent analyst ratings include
- 8/23/2018-EXACT Sciences Corporation (NASDAQ:EXAS) had its Buy rating reiterated by Jefferies Financial Group with a $74.00 price target
- 8/23/2018-EXACT Sciences Corporation (NASDAQ:EXAS) had its Outperform rating reiterated by Leerink Swann with a $90.00 price target
- 8/13/2018-EXACT Sciences Corporation (NASDAQ:EXAS) had its Buy rating reiterated by Canaccord Genuity with a $65.00 price target
Recent Insider Trading Activity For EXACT Sciences Corporation (NASDAQ:EXAS)
EXACT Sciences Corporation (NASDAQ:EXAS) has insider ownership of 3.20% and institutional ownership of 86.35%.
- On 7/30/2018 Jeffrey Thomas Elliott, CFO, sold 8,984 with an average share price of $57.78 per share and the total transaction amounting to $519,095.52.
- On 7/30/2018 Thomas D Carey, Director, sold 3,427 with an average share price of $58.86 per share and the total transaction amounting to $201,713.22.
- On 7/2/2018 D Scott Coward, SVP, sold 2,135 with an average share price of $59.10 per share and the total transaction amounting to $126,178.50.
- On 5/10/2018 Michael S Wyzga, Director, sold 7,402 with an average share price of $51.53 per share and the total transaction amounting to $381,425.06.
- On 4/12/2018 Katherine S Zanotti, Director, sold 7,232 with an average share price of $45.00 per share and the total transaction amounting to $325,440.00.
- On 4/10/2018 Thomas D Carey, Director, sold 8,448 with an average share price of $39.73 per share and the total transaction amounting to $335,639.04.
- On 4/2/2018 D Scott Coward, SVP, sold 2,122 with an average share price of $40.12 per share and the total transaction amounting to $85,134.64.
About EXACT Sciences Corporation (NASDAQ:EXAS)
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Recent Trading Activity for EXACT Sciences Corporation (NASDAQ:EXAS)
Shares of EXACT Sciences Corporation closed the previous trading session at 74,32 −0,77 1,03 % with shares trading hands.